 There is evidence that etrolizumab is effective for ulcerative colitis, with phase 3 trials underway as of 2016.Etrolizumab is a humanized monoclonal antibody that targets he β7 subunit of integrins α4β7 and αEβ7.Etrolizumab decreases lymphocytes trafficking, similar to vedolizumab (another integrin antagonist).